Drug Trial Radar · NCT03195699
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Last checked: Nov 19, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Nov 15, 2017
Primary completion
Jun 24, 2024
Study completion Jun 24, 2024
Sponsor
- Lead sponsor
- Tvardi Therapeutics, IncorporatedIndustry
- Sponsor type
- Industry
- Collaborators
- M.D. Anderson Cancer Center
- First posted
- Jun 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Many patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer. Despite our knowledge of STAT3's importance to cancer, scientists and doctors have not developed a drug that targets it and that patients can take to treat their cancer more effectively than treatments that are now available. Tvardi Therapeutics, Incorporated has developed a compound, TTI-101, which can be given by mouth and acts as a direct inhibitor of STAT3. Administration of TTI-101 to mice demonstrated that it blocked growth of cancers of the breast, head and neck, lung, and liver and it was safe when administered at high doses to mice, rats, and dogs. In this application, Tvardi is proposing to further develop TTI-101 for treatment of solid tumors for which the prognosis is dismal. The investigators will determine how safe it is when administered to patients with cancer, determine whether an adequate dose can be administered to patients with cancer that will block STAT3 in their cancer, and determine whether treatment with TTI-101 leads to reduced growth of their cancer.
Conditions
- Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Non Small Cell Lung Cancer
- Hepatocellular Cancer
- Colorectal Cancer
- Gastric Adenocarcinoma
- Melanoma
- Advanced Cancer
Interventions
TTI-101Drug
Oral capsule
TTI-101Drug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose of TTI-101Time frame: 28 days
- Pharmacokinetics - CmaxTime frame: 18 months
- Pharmacokinetics - TmaxTime frame: 18 months
- Pharmacokinetics - AUC(0-t)Time frame: 18 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
The University of Texas MD Anderson Cancer Center
Houston, Texas
Mays Cancer Center at University of Texas Health Science Center SA
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.